神经丝轻链与帕金森病发生及严重程度的关联
基于芝加哥健康与老龄化项目1327名老年人的纵向人群研究,发现基线血清神经丝轻链(NfL)浓度每升高2倍,与临床帕金森病(OR 2.54,95%CI 1.70-3.81)及整体帕金森体征(OR 2.44,95%CI 1.94-2.94)相关,且该关联在诊断前5年以上即显著。较高NfL浓度还与身体功能下降更快相关(每年下降增加0.15单位,95%CI 0.21-0.08)。
要点
- 血清NfL升高与帕金森病发生风险增加相关,且在诊断前5年以上即可观察到关联。
- 血清NfL水平越高,整体帕金森体征评分及身体功能下降速度越快。
- 该研究提供II级证据支持血清NfL作为神经退行性变的潜在生物标志物。
核心结论
- 血清NfL与临床帕金森病发生、帕金森体征及身体功能下降相关,可能作为神经退行性变的潜在生物标志物。
研究设计与样本
- 基于芝加哥健康与老龄化项目的纵向人群研究,纳入1327名老年人,随访16年,评估帕金森体征、临床帕金森病诊断及身体功能。
主要发现
- 在1254名接受临床帕金森病评估的参与者中,77人(6.1%)发展为临床帕金森病。
- 血清NfL浓度每升高2倍,与临床帕金森病发生相关(OR 2.54,95%CI 1.70-3.81),与整体帕金森体征相关(OR 2.44,95%CI 1.94-2.94)。
- 该关联在帕金森病诊断前5年以上即显著。
- 与基线血清NfL低于18.5 pg/mL者相比,18.5-25.4 pg/mL、25.4-37.3 pg/mL及高于37.3 pg/mL者在诊断时至诊断前5年以上的所有时间间隔内临床帕金森病OR均更高。
- 血清NfL浓度较高与身体功能下降更快相关:NfL浓度升高2倍者,身体功能年下降率增加0.15单位(95%CI 0.21,0.08)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Blood biomarkers may allow earlier identification of Parkinson disease (PD), parkinsonism, and poor PD-related outcomes, such as physical functioning. Neurofilament light (NfL), a neuronal cytoplasmic protein, is a biomarker of neurodegeneration measurable in biofluids. Our objective was to examine the association of serum NfL at baseline with clinically diagnosed PD, parkinsonian signs, and physical functioning change over 16 years in a population-based sample of older adults. METHODS: Data came from 1,327 older participants from the Chicago Health and Aging Project, a longitudinal population-based study. Clinical evaluations included assessing parkinsonian signs in 4 domains-bradykinesia, parkinsonian gait, rigidity, and tremors-using a structured version of the Unified Parkinson's Disease Rating Scale. Board-certified neurologists diagnosed PD. Physical functioning was assessed using chair stands, tandem walk, and timed walk. An ultrasensitive immunoassay was used to measure the concentration of NfL in blood. RESULTS: Of the 1,254 participants examined for clinical PD, 77 (6.1%) developed clinical PD and parkinsonian signs were on average 9.5 (range 0-66.0). After adjusting for demographic characteristics, APOE ε4 allele, and global cognition, a 2-fold higher concentration of serum NfL was associated with incident clinical PD (odds ratio [OR] 2.54, 95% CI 1.70, 3.81) and global parkinsonian signs (OR 2.44, 95% CI 1.94, 2.94). This association was significant >5 years before diagnosis. Compared with participants with levels below 18.5 pg/mL of serum NfL at baseline, participants with levels between 18.5 and 25.4 pg/mL, between 25.4 and 37.3 pg/mL, and above 37.3 pg/mL had a higher OR of clinical PD at all time intervals from the time of diagnosis to >5 years before diagnosis. A higher concentration of serum NfL was associated with a faster rate of physical functioning decline. In participants with 2-fold higher concentrations of serum NfL, the annual rate of decline in physical functioning increased by 0.15 units (95% CI 0.21, 0.08). DICUSSION: Serum NfL was associated with incident clinical PD, parkinsonian signs, and physical functioning decline in a population-based sample. Our findings suggest that NfL may serve as a potential biomarker for neurodegeneration, including PD outcomes. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that serum NfL levels are associated with incident PD, parkinsonian signs, and physical functioning decline.
引用
- Halloway S, Desai P, Beck T, et al. Association of Neurofilament Light With the Development and Severity of Parkinson Disease. Neurology. 2022. PMID: 35418452. doi:10.1212/WNL.0000000000200338
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。